Abstract
Angiogenesis is a hallmark of tumor growth and progression in solid and hematological malignancies. Different cellular components of the tumor microenvironment such as macrophages, mast cells, circulating endothelial cells and angiogenic factors, including vascular endothelial growth factor and its receptors are involved in the maintenance of Hodgkin Lymphoma. In this review article, we highlight relevant literature focusing on the relationships between angiogenesis and Hodgkin Lymphoma as well as discussing anti-angiogenic treatments in this malignancy.
Keywords:
Angiogenesis; Anti-angiogenesis; Hodgkin Lymphoma; Tumor microenvironment.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Histone Deacetylase Inhibitors / therapeutic use
-
Hodgkin Disease / drug therapy
-
Hodgkin Disease / immunology
-
Hodgkin Disease / pathology*
-
Humans
-
Immunomodulation
-
Macrophages / physiology
-
Mast Cells / physiology
-
Neovascularization, Pathologic / drug therapy
-
Neovascularization, Pathologic / etiology*
-
Neovascularization, Pathologic / immunology
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / immunology
Substances
-
Angiogenesis Inhibitors
-
Histone Deacetylase Inhibitors
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A